Alerts will be sent to your verified email
Verify Email
GUJINJEC
|
Guj. Inject (Kerala)
|
Krebs Biochem.&Inds
|
Concord Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
2.58 % | 37.05 % | 2.78 % |
|
5yr average Equity Multiplier
|
0.11 | -2.13 | 1.87 |
|
5yr Average Asset Turnover Ratio
|
0.45 | 0.3 | 0.84 |
|
5yr Avg Net Profit Margin
|
-175.28 % | -55.19 % | 1.59 % |
|
Price to Book
|
10.14 | 0.0 | 2.93 |
|
P/E
|
410.29 | 0.0 | 178.7 |
|
5yr Avg Cash Conversion Cycle
|
-14.62 Days | -1144.52 Days | 233.27 Days |
|
Inventory Days
|
38.61 Days | 102.59 Days | 152.22 Days |
|
Days Receivable
|
0.0 | 8.23 Days | 106.22 Days |
|
Days Payable
|
156.02 Days | 623.06 Days | 74.71 Days |
|
5yr Average Interest Coverage Ratio
|
298.1 | -4.97 | 1.69 |
|
5yr Avg ROCE
|
2.0 % | -23.43 % | 8.41 % |
|
5yr Avg Operating Profit Margin
|
-279.73 % | -34.39 % | 9.1 % |
|
5 yr average Debt to Equity
|
-0.62 | -1.88 | 0.55 |
|
5yr CAGR Net Profit
|
n/a | -0.84 % | -26.55 % |
|
5yr Average Return on Assets
|
-116.01 % | -16.47 % | 1.46 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 72.74 % | 54.39 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.02 % | 5.39 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Guj. Inject (Kerala)
|
Krebs Biochem.&Inds
|
Concord Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|